Allergic
asthma is a heterogeneous inflammatory disorder triggered by inhaled
allergens, leading to airflow obstruction, bronchial
inflammation, and
airway hyperresponsiveness (AHR). T helper (Th) 2 cell-mediated immune response and airway
inflammation are the key features of allergic
asthma.
Bruceine D (BD) is a bioactive compound extracted from the seeds of Brucea javanica. The present study aimed to investigate the effects of increased doses of BD on AHR, secretion of Th1-/Th2-associated
cytokines, and inflammatory cell infiltration in
ovalbumin (OVA)-induced allergic
asthma mice. The results showed that BD reduced OVA-induced inflammatory cell infiltration and bronchial hyperresponsiveness into the peribronchial tissues and perivascular areas. Mice treated with BD also showed significantly decreased expressions of Th2-associated
cytokines (i.e.,
interleukin (IL)-4, IL-5, and
IL-13) and elevated production of Th1-associated
cytokines (i.e.,
interferon gamma and IL-2) following OVA stimulation. BD treatment dose-dependently inhibited OVA-induced accumulation of inflammatory cells in asthmatic mice. Further analysis revealed that OVA exposure upregulated pulmonary expressions of NOTCH signaling receptors, a group of transmembrane
proteins that communicate signals upon binding to transmembrane
ligands expressed on adjacent cells, while BD treatment significantly abolished OVA-induced activation of the NOTCH pathway. In conclusion, BD protected mice against OVA-induced allergic
asthma by reducing AHR and restoring the Th1/Th2 balance through the NOTCH signaling pathway. Our findings highlighted the potential of BD as a therapeutic agent for allergic
asthma.